Re:: Liu et al. -: Estrogen receptor status in inoperable hepatocellular carcinoma -: Response

被引：0
|
作者：
Liu, CL
Ng, IOL
Fan, ST
机构：
[1] Univ Hong Kong, Med Ctr, Dept Surg, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Med Ctr, Dept Pathol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Ctr Liver Dis, Hong Kong, Hong Kong, Peoples R China
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2001年 / 96卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1297 / 1298
页数：2
相关论文
共 50 条
  • [21] Response to Wang et al. Re: How to choose and compare between radiofrequency ablation and transarterial chemoembolization for recurrent hepatocellular carcinoma?
    Koh, P. S.
    Chan, A. C.
    HPB, 2017, 19 (12) : 1133 - 1133
  • [22] Response to Machado et al. re: Jahi McMath
    Ariane Lewis
    Neurocritical Care, 2018, 29 : 523 - 524
  • [23] RE: Response to letter to the editor by Kay et al.
    Dillman, Robert O.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (05) : 715 - 717
  • [24] Re: Stirling et al. 2021 Article RESPONSE
    Stirling, Ian
    ARCTIC, 2021, 74 (04) : 566 - 567
  • [25] Response to Machado et al. re: Jahi McMath
    Lewis, Ariane
    NEUROCRITICAL CARE, 2018, 29 (03) : 523 - 524
  • [26] Re:: Garcia-Samaniego et al. -: Hepatocellular carcinoma in patients with HCV-HIV coinfection
    Toyoda, H
    Hayashi, K
    Nakano, I
    Fukuda, Y
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (12): : 3441 - 3441
  • [27] In response to Murphy et al., Lower et al., and Lan et al.
    Conrad, B
    CELL, 1998, 95 (01) : 16 - 16
  • [28] Author Response to Liu et al
    Webber, Sandra
    PHYSICAL THERAPY, 2022, 102 (01):
  • [29] Liu et al. Respond to "Epstein-Barr Virus Screening for Nasopharyngeal Carcinoma"
    Liu, Zhiwei
    Ye, Weimin
    Zeng, Yi-Xin
    Cao, Su-Mei
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2013, 177 (03) : 254 - 255
  • [30] Response to Rowland et al. and Achour et al.
    Pridgeon, Chris S.
    Johansson, Inger
    Ingelman-Sundberg, Magnus
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1155 - 1155
12345